Search

Your search keyword '"Jacobs, Gabriel E."' showing total 18 results
Start Over Author "Jacobs, Gabriel E." Publication Year Range Last 10 years
18 results on '"Jacobs, Gabriel E."'

3. Molecular Imaging of Depressive Disorders

Author

Ruhé, Henricus G., Frokjaer, Vibe G., Haarman, Bartholomeus (Benno) C. M., Jacobs, Gabriël E., Booij, Jan, Dierckx, Rudi A.J.O., editor, Otte, Andreas, editor, de Vries, Erik F. J., editor, van Waarde, Aren, editor, and Sommer, Iris E., editor

Published
2021
Full Text
View/download PDF

7. Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans

Author

Salvadore, Giacomo, Bonaventure, Pascal, Shekhar, Anantha, Johnson, Philip L., Lord, Brian, Shireman, Brock T., Lebold, Terry P., Nepomuceno, Diane, Dugovic, Christine, Brooks, Sander, Zuiker, Rob, Bleys, Cathy, Tatikola, Kanaka, Remmerie, Bart, Jacobs, Gabriel E., Schruers, Koen, Moyer, John, Nash, Abigail, Van Nueten, Luc G. M., and Drevets, Wayne C.

Published
2020
Full Text
View/download PDF

9. sj-docx-1-tpp-10.1177_20451253211036814 ��� Supplemental material for MTORC1 signaling as a biomarker in major depressive disorder and its pharmacological modulation by novel rapid-acting antidepressants

Author

Cholewinski, Tomasz, Pereira, Diana, Moerland, Matthijs, and Jacobs, Gabriel E.

Subjects
FOS: Clinical medicine, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tpp-10.1177_20451253211036814 for MTORC1 signaling as a biomarker in major depressive disorder and its pharmacological modulation by novel rapid-acting antidepressants by Tomasz Cholewinski, Diana Pereira, Matthijs Moerland and Gabriel E. Jacobs in Therapeutic Advances in Psychopharmacology

Published
2021
Full Text
View/download PDF

10. A Study of Novel Exploratory Tools, Digital Technologies, and Central Nervous System Biomarkers to Characterize Unipolar Depression

Author

Sverdlov, Oleksandr, primary, Curcic, Jelena, additional, Hannesdottir, Kristin, additional, Gou, Liangke, additional, De Luca, Valeria, additional, Ambrosetti, Francesco, additional, Zhang, Bingsong, additional, Praestgaard, Jens, additional, Vallejo, Vanessa, additional, Dolman, Andrew, additional, Gomez-Mancilla, Baltazar, additional, Biliouris, Konstantinos, additional, Deurinck, Mark, additional, Cormack, Francesca, additional, Anderson, John J., additional, Bott, Nicholas T., additional, Peremen, Ziv, additional, Issachar, Gil, additional, Laufer, Offir, additional, Joachim, Dale, additional, Jagesar, Raj R., additional, Jongs, Niels, additional, Kas, Martien J., additional, Zhuparris, Ahnjili, additional, Zuiker, Rob, additional, Recourt, Kasper, additional, Zuilhof, Zoë, additional, Cha, Jang-Ho, additional, and Jacobs, Gabriel E., additional

Published
2021
Full Text
View/download PDF

13. Valproïnezuurintoxicatie door misinterpretatie van plasmaspiegel: Verhoogde ongebonden fractie door hypoalbuminemie en nierfunctiestoornis

Author

Ruiter-Visser, Roos, Dols, Annemieke, Smulders, Yvo M., Jacobs, Gabriel E., Nauta, Klaas Jan, Psychiatry, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, APH - Mental Health, Internal medicine, ACS - Atherosclerosis & ischemic syndromes, and ACS - Diabetes & metabolism

Subjects
lipids (amino acids, peptides, and proteins)
Abstract

CASE DESCRIPTION: A 65-year-old male with a type 1 bipolar disorder developed a number of neurological symptoms including sluggishness, muscle weakness, difficulty in walking and disorders of micturition after his mood stabiliser was changed to valproic acid. Recognition of drug toxicity was delayed as his total plasma valproic acid levels were within the therapeutic range. Later it became apparent that the patient had toxic unbound valproic acid levels due to hypoalbuminaemia and impaired renal function.

Published
2018

15. Psychiatrische beelden bij afwijkende cortisolproductie: Een vaak laat gestelde diagnose

Author

Lommerse, Kinke M., Dijkstra, Francis M., Boeke, A. J.P., Eekhoff, E. M.W., Jacobs, Gabriel E., Internal medicine, MOVE Research Institute, ICaR - Ischemia and repair, and ICaR - Circulation and metabolism

Abstract

This clinical case presentation describes the disease trajectory in two patients who presented with psychiatric symptoms as a result of abnormal serum glucocorticoid levels. One case involves a 58-year-old man with hypercortisolism, the other case concerns a 55-year-old woman with hypocortisolism. In both cases there was a considerable diagnostic delay in recognizing the underlying adrenal gland pathology. Abnormal glucocorticoid levels, caused by endocrine disorders, often results in psychiatric symptoms. Delay in diagnosis may have adverse consequences. Hyper- or hypocortisolism should be considered in patients who present with an atypical presentation of psychiatric symptoms. Moreover, the absence of specific physical signs or symptoms at first presentation in such patients does not exclude an underlying endocrinological cause. Therefore, physical and psychiatric reassessment of such patients should be considered at regular intervals.

Published
2016

18. [Valproic acid toxicity due to misinterpretation of plasma levels: increase in unbound fraction caused by hypoalbuminaemia and renal dysfunction].

Author

Ruiter-Visser R, Dols A, Smulders YM, Jacobs GE, and Nauta KJ

Subjects
Aged, Anticonvulsants blood, Bipolar Disorder blood, Bipolar Disorder complications, Humans, Hypoalbuminemia complications, Male, Mobility Limitation, Muscle Weakness chemically induced, Urination Disorders chemically induced, Valproic Acid blood, Anticonvulsants adverse effects, Bipolar Disorder drug therapy, Hypoalbuminemia blood, Nervous System Diseases chemically induced, Valproic Acid adverse effects
Abstract

Background: Valproic acid is one of the most widely prescribed drugs for the treatment of epilepsy and bipolar disorder. As only the unbound fraction of a medicinal product is pharmacologically active, in some strong protein-bound psychotropic drugs such as valproic acid and phenytoin, a rise in this fraction can lead to severe toxicity., Case Description: A 65-year-old male with a type 1 bipolar disorder developed a number of neurological symptoms including sluggishness, muscle weakness, difficulty in walking and disorders of micturition after his mood stabiliser was changed to valproic acid. Recognition of drug toxicity was delayed as his total plasma valproic acid levels were within the therapeutic range. Later it became apparent that the patient had toxic unbound valproic acid levels due to hypoalbuminaemia and impaired renal function., Conclusion: Clinicians should always consider drug toxicity in patients who show neurological symptoms and use highly protein-bound psychotropic drugs, even if the total plasma concentration of the drug is in the therapeutic range.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results